Dogwood Therapeutics
DWTX1.5400.65% ( -0.010 )
Dogwood Therapeutics (DWTX)
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its l...
- Open
- 1.590
- High
- 1.590
- Low
- 1.460
- Prev. Close
- 1.550
- Volume
- 67.11K
- Turnover
- 101.15K
- Avg Price
- 1.507
- Bid/Ask Ratio
- --
- Amplitude
- 8.39%
- 52wk High
- 9.500
- Volume Ratio
- 1.38
- Turnover Ratio
- 1.40%
Dogwood Therapeutics Analyst Rating
View MoreForecast & Rating
May 19, 2026Price forecast
$14.00809.09%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 2 days ago, 04:12 AM
Under-the-Radar Shifts: From AI Infrastructure Pivots to Niche ETFs
- Unusual Whales · Jul 20 at 07:32 AM
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
- PUBT · Jul 20 at 07:31 AM
Dogwood Therapeutics announces press release availability
- PUBT · Jun 30 at 07:37 PM
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline
- StockTitan · Jun 29 at 11:45 PM
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board | DWTX Stock News
- PUBT · Jun 17 at 03:56 PM
Dogwood Therapeutics shareholders approve charter amendment increasing authorized shares
